This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Related articles  • Similar articles in JAMA  Topic Collections  • Oncology  • Breast Cancer  • Drug Therapy  • Adverse Effects  • Alert me on articles by topic  Social Bookmarking   What's this?

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

In Reply: Dr Duncan and colleagues raise questions about the categorization of hydrophilicity and lipophilicity in the subgroup analysis. There are 3 levels of lipophilicity for statins. Pravastatin and rosuvastatin have low lipophilicity, atorvastatin and fluvastatin have modest lipophilicity, and simvastatin and lovastatin have high lipophilicity.¹ Pravastatin, fluvastatin, and atorvastatin do not penetrate the blood-brain barrier.² From postmarketing surveillance, the risk of death from rhabdomyolysis is quite similar between pravastatin, fluvastatin, and atorvastatin, but lower than that of simvastatin and lovastatin.³ We therefore believe that fluvastatin and atorvastatin act more like hydrophilic agents than lipophilic ones. However, when we analyzed pravastatin alone for breast cancer incidence, the results (odds ratio [OR], 1.38; 95% confidence interval [CI], 0.72-2.65) were similar to our overall statin findings, as they were for colon, gastrointestinal, and respiratory cancer incidence. Pravastatin therefore does not appear to exhibit procancer effects that might have countered the anticancer effects . . . [Full Text of this Article]

Krista Dale, PharmD; C. Michael White, PharmD
cmwhite@harthosp.org
Drug Information Center
University of Connecticut
Storrs

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLES

Statins and the Risk of Cancer
Robin E. Duncan, Ahmed El-Sohemy, and Michael C. Archer
JAMA. 2006;295(23):2720.
EXTRACT | FULL TEXT  

Statins and the Risk of Cancer
Michael R. Freeman, Keith R. Solomon, and Mark Moyad
JAMA. 2006;295(23):2720-2721.
EXTRACT | FULL TEXT  

Statins and the Risk of Cancer
Claudia A. Salinas, Ilir Agalliu, Janet L. Stanford, and Daniel W. Lin
JAMA. 2006;295(23):2721.
EXTRACT | FULL TEXT  

Statins and Cancer Risk: A Meta-analysis
Krista M. Dale, Craig I. Coleman, Nickole N. Henyan, Jeffrey Kluger, and C. Michael White
JAMA. 2006;295(1):74-80.
ABSTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Association Between Statin Use and Risk for Keratinocyte Carcinoma in the Veterans Affairs Topical Tretinoin Chemoprevention Trial
Dore et al.
ANN INTERN MED 2009;150:9-18.
ABSTRACT | FULL TEXT